Navigation Links
New drug targets may fight tuberculosis and other bacterial infections in novel way
Date:12/27/2007

NEW YORK (Dec. 27, 2007) -- Over the course of the 20th Century, doctors waged war against infectious bacterial illness with the best new weapon they had: antibiotics.

But the emergence of dangerous, multi-drug resistant strains of tuberculosis and other killer infections means that in the 21st century antibiotics are losing ground against bacterial disease.

Now, researchers from Weill Cornell Medical College in New York City say exciting new molecular targets -- so-called "virulence factors" that bacteria use to thrive once they are in the host -- present an alternative, potent means of stopping TB, leprosy and other bacterial illness.

"We have developed the first inhibitor of a key small molecule from Mycobacterium tuberculosis and Mycobacterium leprae (which causes leprosy) utilized to subvert human host's defenses and damage and invade human host's cells during infection," explains study senior author Dr. Luis Quadri, Associate Professor of Microbiology and Immunology at Weill Cornell.

"With this work, we now have proof of principle for the inhibition of this virulence factor in bacteria cultured in the lab. Our next step is to explore whether this inhibitor can stop these pathogens from multiplying in a mouse host, curtailing infection," Dr. Quadri says.

The findings -- published online today in Chemistry and Biology and appearing in the journal's Jan. 26 print edition -- highlight what Dr. Quadri has called a "paradigm shift" in infectious disease research.

"We are moving beyond antimicrobials such as antibiotics, which kill the bacterium directly, to anti-infectives, that may have no effect against the pathogen in the test tube but which do compromise its ability to infect and spread in the host," he explains. "We believe that the expansion of the drug armamentarium to include such anti-infective drugs could help the fight against multi-drug resistant infection that has become such a challenge tod
'/>"/>

Contact: Andrew Klein
ank2017@med.cornell.edu
212-821-0560
New York- Presbyterian Hospital/Weill Cornell Medical Center/Weill Cornell Medical College
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Nicotinic receptors may be important targets for treatment of multiple addictions
2. Central targets may hinder wider waste management objectives
3. UIC researchers find promising new targets for antibiotics
4. New X-ray technique targets terrorists and tumors
5. Clemson chemists discover new way antioxidants fight debilitating diseases
6. Social habits of cells may hold key to fighting diseases
7. Advance in effort to fight malaria by tricking the mosquitos sense of smell
8. Yale scientists use nanotechnology to fight E. coli
9. Researchers develop liquid crystal pharmaceuticals to fight cancer and other diseases
10. Japanese beetle may help fight hemlock-killing insect
11. When it comes fighting to C. difficile, the Palme dOr goes to soap and warm water
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 11, 2014 Researchers have pioneered a revolutionary ... new technology, called Virtual Finger, allows scientists to ... neurons and synapses using the flat surface of ... 3D imaging studies orders of magnitude more efficient, ... level across many areas of experimental biology. The ...
(Date:7/11/2014)... that under the normal circumstances, astrocytes participate ... neuronal environment, and exhibit therapeutic and repairing ... Previous studies have found that nerve cells ... induction have reduced viability, which produces influences ... Yuan, Kailuan General Hospital, Hebei United University, ...
(Date:7/11/2014)... Janeiro, Brazil- In the brains of all vertebrates, ... allows an electric or chemical signal to be ... synapses, which are the most abundant type of ... formation is crucial for learning, memory, perception and ... synapses critical for brain function. For instance, ...
Breaking Biology News(10 mins):Virtual finger enables scientists to navigate and analyze complex 3D images 2Blame it on the astrocytes 2
... Energy,s Brookhaven National Laboratory have identified two promising candidates ... cause of ailments ranging from colds to gastrointestinal disorders ... Letters , a journal of the Federation of European ... of compounds to determine which might block the effects ...
... in metabolic pathways as a result of oncogenes that ... 2) works as a "master gene" that turns on ... to protect the lungs from variety of air pollutants ... at the Johns Hopkins Bloomberg School of Public Health ...
... CATransport proteins are responsible for moving materials such as ... which seals and protects all living cells, to the ... be used to fuel growth or to respond to ... cell. Measuring the activity of transporter proteins in a ...
Cached Biology News:Scientists identify promising antiviral compounds 2Scientists identify promising antiviral compounds 3Hijacking stress response in cancer 2Breakthrough: Sensors monitor cells at work 2
(Date:7/11/2014)... , July 11, 2014 , ... part) in, into or from any jurisdiction where to do ... such jurisdiction.  Shire plc ("Shire" or the "Company") ... article this afternoon.  Shire confirms it has held a meeting ... made by Shire without the prior agreement or approval of ...
(Date:7/11/2014)... BCC Research ( http://www.bccresearch.com ) reveals in its ... TECHNOLOGY: GLOBAL MARKETS , the global market for digital ... in 2013. This is estimated to grow to $490 ... rate (CAGR) of 28.6%. , New digital PCR technology ... within the broader PCR field. The opportunities presented by ...
(Date:7/11/2014)... , July 11, 2014 /CNW/ - Sunovion Pharmaceuticals ... APTIOM TM (eslicarbazepine acetate) for use as a ... in patients with epilepsy who are not satisfactorily controlled ... for use in patients under 18 years of age. ... common neurological disorders and according to Epilepsy Canada, it ...
(Date:7/11/2014)... Scottsdale, AZ (PRWEB) July 11, 2014 ... medicine device company specializing in the soft tissue ... SureLock All-Suture Anchor System for surgeries involving the ... predictable fixation through a novel, inserter-controlled deployment method. ... lead to partial deployment, anchor pull-out, or anchor ...
Breaking Biology Technology:Shire plc - Statement re: Media Speculation 2Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 2Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 2Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 3
... Enrollment in First Cohort --, SAN DIEGO, ... today announced that the Company,has completed enrollment of ... trial,to assess the safety and tolerability of new ... The trial is expected to dose up to ...
... (OTC Bulletin Board: NILT.OB), a biopharmaceutical company focused ... Mr.,Pedro Granadillo was appointed on October 16, 2007 ... is a highly-respected pharmaceutical industry,leader with over 30 ... and quality assurance. "We are pleased to ...
... AMICAS, Inc. (Nasdaq: AMCS ),a leader in radiology ... will present to and meet with investors at,the CIBC ... New,York. (Logo: http://www.newscom.com/cgi-bin/prnh/20060202/AMICASLOGO ), WHEN: ... begins promptly at 10:20 a.m. (Eastern Time), 9:20 a.m. ...
Cached Biology Technology:Nventa updates progress of cervical dysplasia trial with new HspE7 2Nventa updates progress of cervical dysplasia trial with new HspE7 3Nventa updates progress of cervical dysplasia trial with new HspE7 4Nventa updates progress of cervical dysplasia trial with new HspE7 5Nile Therapeutics Appoints Pedro Granadillo to Board of Directors 2Nile Therapeutics Appoints Pedro Granadillo to Board of Directors 3
(3-[125I]iodotyrosyl26)Galanin, porcine, 370 kBq, 10 uCi. Category: IODINE LIGANDS....
Human FADD Affinity Purified Polyclonal Ab...
Human VEGF R3/Flt-4 Phycoerythrin MAb (Clone 54733)...
Immunogen: Synthetic Peptide: V(22) N G H E F E I E G E G E G R(36) Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biology Products: